COPENHAGEN, April 22 (Reuters) - Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.
The company has said previously it expects sales from the drug to eventually reach $1 billion a year.
19:53 Costco Wholesale expands test of home grocery delivery through new third-party service20
06:22 Hyundai Motor shares hit 22-month high on restructuring hope17
09:48 Uber President Jeff Jones Quits After Just Six Months on the Job22
00:36 Uber president Jeff Jones quits, deepening turmoil24